Title:In vitro and In vivo Evaluation of the Antidiabetic Activity of Solidago virgaurea
Extracts
Volume: 19
Issue: 4
Author(s): Syeda Andleeb Zehra, Prapanna Bhattarai, Jian Zhang, Yin Liu, Zahida Parveen, Muhammad Sajid and Lin Zhu*
Affiliation:
- Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M University, College
Station, Texes-78363, USA
Keywords:
Solidago virgaurea, protein tyrosine phosphatase 1B, glucose transporter, α-glucosidase, advanced glycation end products, GC-MS.
Abstract:
Background: Solidago virgaurea (Asteraceae) has been used for more than 700 years
for treating cystitis, chronic nephritis, urolithiasis, rheumatism, and inflammatory diseases. However,
the antidiabetic activity of Solidago virgaurea has been rarely studied.
Methods: Three extracts of Solidago virgaurea were prepared, and their antidiabetic potentials
were evaluated by various cell-free, cell-based, and in vivo studies.
Results: We found that the Solidago virgaurea contained multiple bioactive phytochemicals based
on the GC-MS analysis. The Solidago virgaurea extracts effectively inhibited the functions of the
carbohydrate digestive enzyme (α-glucosidase) and protein tyrosine phosphatase 1B (PTP1B), as
well as decreased the amount of advanced glycation end products (AGEs). In the L6 myotubes, the
Solidago virgaurea methanolic extract remarkably enhanced the glucose uptake via the
upregulation of glucose transporter type 4 (GLUT4). The extract also significantly downregulated
the expression of PTP1B. In the streptozotocin-nicotinamide induced diabetic mice, the daily
intraperitoneal injection of 100 mg/kg Solidago virgaurea methanolic extract for 24 days,
substantially lowered the postprandial blood glucose level with no obvious toxicity. The extract’s
anti-hyperglycemic effect was comparable to that of the glibenclamide treatment.
Conclusion: Our findings suggested that the Solidago virgaurea extract might have great potential
in the prevention and treatment of diabetes.
